Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Clinical trial NCT02738801 · COMPLETED
Trial details
- NCT number
- NCT02738801
- Sponsor
- Lakefront Biotherapeutics NV
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-01
- Primary completion
- 2017-05-02
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.